What is the recommended adult dosing of imipenem‑cilastatin, including adjustments for renal impairment?

Imipenem-Cilastatin Dosing in Adults

For adults with normal renal function (creatinine clearance ≥90 mL/min), administer imipenem-cilastatin 500 mg every 6 hours OR 1000 mg every 8 hours for susceptible pathogens, with dose reductions required for any degree of renal impairment. 1

Standard Adult Dosing (Normal Renal Function)

For patients with creatinine clearance ≥90 mL/min, dosing depends on pathogen susceptibility 1:

• Susceptible organisms: 500 mg every 6 hours OR 1000 mg every 8 hours 2, 1
• Intermediate susceptibility organisms: 1000 mg every 6 hours 1
• Maximum daily dose: Do not exceed 4 g/day 1

Infusion Guidelines

• 500 mg doses: Infuse over 20-30 minutes 1
• 1000 mg doses: Infuse over 40-60 minutes 1
• If nausea develops during infusion, slow the infusion rate 1

Renal Impairment Dosing

Dose reduction is mandatory for any creatinine clearance <90 mL/min 1. Calculate creatinine clearance using the Cockcroft-Gault equation 1:

Dosing by Renal Function

For susceptible organisms 1:

• CLcr 60-89 mL/min: 400 mg every 6 hours OR 500 mg every 6 hours
• CLcr 30-59 mL/min: 300 mg every 6 hours OR 500 mg every 8 hours
• CLcr 15-29 mL/min: 200 mg every 6 hours OR 500 mg every 12 hours

For intermediate susceptibility organisms 1:

• CLcr 60-89 mL/min: 750 mg every 8 hours
• CLcr 30-59 mL/min: 500 mg every 6 hours
• CLcr 15-29 mL/min: 500 mg every 12 hours

Critical Renal Impairment Warnings

• CLcr <15 mL/min: Do NOT use imipenem-cilastatin unless hemodialysis will be instituted within 48 hours 1
• Increased seizure risk exists in patients with CLcr <30 mL/min 1
• The half-life of imipenem increases from approximately 1 hour in normal function to 3.7 hours in dialysis patients, while cilastatin half-life increases dramatically from 0.86 hours to 17 hours 3

Hemodialysis Patients

• Use the dosing recommendations for CLcr 15-29 mL/min 1
• Administer doses AFTER hemodialysis, timed from the end of the dialysis session 1
• Both imipenem and cilastatin are efficiently cleared during hemodialysis (half-life reduced from 4.8 to 2.45 hours for imipenem and 16.6 to 3.86 hours for cilastatin) 3
• Supplemental 500 mg dose recommended after dialysis 4
• Monitor carefully for seizures, especially in patients with baseline CNS disease 1

Important Clinical Considerations

Loading Dose Strategy

Although not specified in FDA labeling, critically ill patients benefit from a loading dose equal to the standard intermittent dose before starting maintenance therapy, regardless of renal function 2. This accounts for increased volume of distribution in septic patients 2.

Continuous Infusion Limitations

Imipenem-cilastatin is NOT suitable for prolonged continuous infusion due to poor chemical stability 2:

• Stability at 25°C in 0.9% NaCl: only 2-3 hours 2
• Requires administration in divided doses prepared immediately before infusion 2

Augmented Renal Clearance

In critically ill patients with augmented renal clearance (CLcr ≥130 mL/min), standard dosing of 1.25 g every 6 hours achieves adequate exposure for pathogens with MIC ≤2 mg/L 5. No dose increase is necessary despite enhanced clearance 5.

Key Pitfalls to Avoid

• Never use in patients with CLcr <15 mL/min without planned hemodialysis - risk of cilastatin accumulation and seizures 1, 3
• Always adjust for renal function - even mild impairment (CLcr 60-89 mL/min) requires dose reduction 1
• Do not use in CNS infections - not indicated for meningitis due to seizure risk 1
• Avoid co-administration with valproic acid - imipenem reduces valproic acid levels, increasing breakthrough seizure risk 1